Cystadrops (Cysteamine HCl) Patent Expiration, LOE Window & CMS Spending
Cystadrops (Cysteamine HCl) by Recordati Rare Diseases: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $10.9M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Recordati Rare Diseases |
| FDA Application & Pathway | N211302 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $10.9M |
| 2024 Medicare Part D Spend | $2.7M |
| 2024 Medicaid Spend | $8.2M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 29.7% 2-yr change) |